Report overview
The global Endothelin Antagonist Therapy market was valued at US$ million in 2023 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2023, While China is to reach $ Million.
Oral Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Endothelin Antagonist Therapy include Gilead Sciences, Sun Pharmaceutical Industries, Lupin, Zydus Group, Endo International, Mylan N.V, Teva Pharmaceutical Industries, Sigmapharm Laboratories and Alembic Pharmaceuticals, etc. in 2023, the global top five players have a share approximately % in terms of revenue.
This report aims to provide a comprehensive presentation of the global market for Endothelin Antagonist Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Endothelin Antagonist Therapy. This report contains market size and forecasts of Endothelin Antagonist Therapy in global, including the following market information:
Global Endothelin Antagonist Therapy Market Revenue, 2019-2024, 2025-2030, ($ millions)
Global top five companies in 2023 (%)
We surveyed the Endothelin Antagonist Therapy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Endothelin Antagonist Therapy Market, by Type, 2019-2024, 2025-2030 ($ millions)
Global Endothelin Antagonist Therapy Market Segment Percentages, by Type, 2023 (%)
Oral
Parenteral
Global Endothelin Antagonist Therapy Market, by Application, 2019-2024, 2025-2030 ($ millions)
Global Endothelin Antagonist Therapy Market Segment Percentages, by Application, 2023 (%)
Hospitals
Specialty Clinics
Diagnostic Centers
Others
Global Endothelin Antagonist Therapy Market, By Region and Country, 2019-2024, 2025-2030 ($ Millions)
Global Endothelin Antagonist Therapy Market Segment Percentages, By Region and Country, 2023 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Endothelin Antagonist Therapy revenues in global market, 2019-2024 (estimated), ($ millions)
Key companies Endothelin Antagonist Therapy revenues share in global market, 2023 (%)
Further, the report presents profiles of competitors in the market, key players include:
Gilead Sciences
Sun Pharmaceutical Industries
Lupin
Zydus Group
Endo International
Mylan N.V
Teva Pharmaceutical Industries
Sigmapharm Laboratories
Alembic Pharmaceuticals
Hikma Pharmaceuticals
Amneal Pharmaceuticals
AstraZeneca
Johnsons & Johnsons Private limited
Outline of Major Chapters:
Chapter 1: Introduces the definition of Endothelin Antagonist Therapy, market overview.
Chapter 2: Global Endothelin Antagonist Therapy market size in revenue.
Chapter 3: Detailed analysis of Endothelin Antagonist Therapy company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Endothelin Antagonist Therapy in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
